Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Hurricanes lose defenseman Brett Pesce to lowerNelly Korda puts sixRainy season spells misery for hundreds at Myanmar camp for displaced — Radio Free AsiaScottie Scheffler did NOT consider withdrawing from RBC Heritage to be with heavilyInside Kate Middleton's sweet annual midnight tradition for Prince Louis' birthdayNATO newcomer Finland is now a 'frontUEFA picks two video review referees at center of controversy for Euro 2024 dutyKylie Jenner flaunts her eyeReview of UNWRA finds Israel did not express concern about staffElection 2024: Republican candidates vying for Indiana governor to take debate stage